Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis
Authors' conclusion
In this cohort of patients treated according to an early treat-to-target strategy, clinical, structural, and functional outcomes remained favourable at 10 years. Achievement of sustained remission in early disease was associated with higher remission rates and better physical function at 10 years.
Study context
- Population
- Patients with early rheumatoid arthritis (RA) treated with a strict treat-to-target strategy for 2 years in the ARCTIC trial179 (82%) participated in follow-up
- Participants
- 230 patients
- Comparison
- Sustained Disease Activity Score (DAS) remission at 2 years vs no sustained remission
- Primary endpoint
- Clinical, structural and functional outcomes (disease activity, radiographic damage, physical function, survival)
- Follow-up
- 10 years
Methodological details10-year follow-up, stratified by sustained remission
- 10-year follow-up
- Stratified by sustained remission
Primary result
As reported in the abstract
Clinical, structural and functional outcomes
DAS remission 10 years after diagnosis
82%
Change in total van der Heijde modified Sharp score from baseline, median (IQR)
2.0
0.5, 4.5
Alive at 10 years
218
95%
Further findings
- Sustained DAS remission at 2 years: lower disease activity and higher physical function at 10 years than those who did not
Original publication
Ten-year outcomes after treat-to-target therapy in early rheumatoid arthritis. Ann Rheum Dis. Published 22 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →